Literature DB >> 21161535

Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity.

Eiichi Tanaka1, Ajitha Mannalithara, Eisuke Inoue, Noriko Iikuni, Atsuo Taniguchi, Shigeki Momohara, Gurkirpal Singh, Hisashi Yamanaka.   

Abstract

We investigated the effect of long-term corticosteroid usage in suppressing the progression of functional disability in patients with early rheumatoid arthritis (RA). We studied 3,982 RA patients, who had continuous enrollment for at least 3 years, among 9,132 RA patients enrolled in an observational cohort study, IORRA, in Tokyo, Japan, from 2000 to 2007. The DAS28 and Japanese version of Health Assessment Questionnaire (J-HAQ) scores were collected at 6-month intervals (each phase). Among these patients, those with DAS28 values under 3.2 in all phases and RA disease duration under 2 years at study entry were selected as "early RA patients with well-controlled disease". These patients were further classified into 3 groups based on average months of steroid usage per year: Non-users, Medium-users, and Frequent-users. Multiple linear regression analysis was used to study the relationship between steroid usage and the final J-HAQ scores. Among the 3,982 patients, 109 had DAS28 values under 3.2 in all the phases and were selected as study cohort. The average Final J-HAQ in Non-user (N = 64), in Medium-user (N = 25), in Frequent-user group (N = 20) was 0.04, 0.06, and 0.33, respectively. Multiple linear regression analysis after adjusting for all potential covariates confirmed that frequent steroid usage was the most significant factor associated with higher final J-HAQ scores (P < 0.05). Frequent steroid usage was associated with significantly higher final J-HAQ scores in early RA patients, even though their disease was managed efficiently by maintaining the DAS28 values under 3.2 over a long-term period.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21161535     DOI: 10.1007/s00296-010-1638-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  68 in total

1.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors:  M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal:  Lancet       Date:  1997-08-02       Impact factor: 79.321

4.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.

Authors:  D M van der Heijde; M A van't Hof; P L van Riel; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

5.  Are glucocorticoids DMARDs?

Authors:  Johannes W J Bijlsma; Jos N Hoes; Amalia A Van Everdingen; Suzan M M Verstappen; Johannes W G Jacobs
Journal:  Ann N Y Acad Sci       Date:  2006-06       Impact factor: 5.691

6.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.

Authors:  K G Saag; R Koehnke; J R Caldwell; R Brasington; L F Burmeister; B Zimmerman; J A Kohler; D E Furst
Journal:  Am J Med       Date:  1994-02       Impact factor: 4.965

7.  Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheumatoid arthritis.

Authors:  N Iikuni; E Inoue; E Tanaka; M Hara; T Tomatsu; N Kamatani; H Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2008-04       Impact factor: 7.580

8.  Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.

Authors:  C Michael Lambert; Sharron Sandhu; Alison Lochhead; Nigel P Hurst; Euan McRorie; Veena Dhillon
Journal:  Arthritis Rheum       Date:  2004-02

9.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

10.  Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis.

Authors:  L M Buckley; E S Leib; K S Cartularo; P M Vacek; S M Cooper
Journal:  J Rheumatol       Date:  1995-06       Impact factor: 4.666

View more
  1 in total

1.  Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan.

Authors:  Hirotaka Katada; Naoichiro Yukawa; Hisashi Urushihara; Shiro Tanaka; Tsuneyo Mimori; Koji Kawakami
Journal:  Clin Rheumatol       Date:  2014-01-14       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.